Status: Recruiting
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
To find the recommended dose of hyper-CVAD in combination with venetoclax that can be given to participants with relapsed or refractory leukemia.
Participants needed: 22
Trial details
Phase: Phase 1Age: 2-21Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 24, 2026Locations: 1
Eligibility criteria
Pediatric, adolescent, or young adult patients with relapsed or refractory acute... [+21]
curatively treated non-melanomatous skin cancer, [+12]